Cellworks Group

Jan 13, 2025 | markets.financialcontent.com | Cellworks Group

Jan 13, 2025 | markets.financialcontent.com | Cellworks Group

CLIA Certification Broadens Cellworks’ Capabilities to Deliver Personalized Therapy Predictions that Improve Cancer Treatment OutcomesCellworks Group, Inc., a leader in Personalized Therapy Decision Support and Precision Drug Development, today announced that its computational laboratory in Franklin, Tennessee, has obtained certification of compliance from the Centers for Medicare and Medicaid Services (CMS) under the Clinical Laboratory Improvement Amendments (CLIA).

Oct 31, 2023 | frontiersin.org | Cellworks Group |David Eisenstat |Hiroaki Wakimoto |Rebecca Brown

BackgroundLeptomeningeal spread of glioblastoma (LM-GBM) is a life-threatening disease renowned for dire neurological sequelae and short median survival of 1.6 to 3.8 months (1). Though responses to chemotherapy are documented and generally favor a disposition of intervention, single agents accomplish relatively little against complex diseases like LM-GBM.